Navigation Links
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 2013 Edition

DUBLIN, April 25, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition" report to their offering.


The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

- In-depth understanding of preclinical stage deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a preclinical stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech includes

- Trends in preclinical stage dealmaking in the biopharma industry since 2007
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,200 preclinical stage deals
- The leading preclinical stage deals by value since 2007
- Most active preclinical stage dealmakers since 2007
- The leading preclinical stage partnering resources

In Preclinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:

- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

Chapter 3 - Preclinical stage deal strategies and structure

Chapter 4 - Preclinical stage partnering payment strategies

Chapter 5 - Trends in preclinical stage deal making

Chapter 6 - Average payment terms for preclinical stage partnering

Chapter 7 - Leading preclinical stage deals

Chapter 8 - Big pharma and big biotech preclinical stage partnering deals

Chapter 9 - Preclinical stage partnering contracts directory

Chapter 10 - Preclinical stage dealmaking directory

For more information visit Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition

Research and Markets
Laura Wood , Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
3. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
7. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
8. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
9. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
10. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
11. Translating Preclinical Pharmacology to Clinical Activity with Myriad RBM’s Inflammation MAP
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):